BioCentury
ARTICLE | Clinical News

GW's GWP42006 misses in Phase IIa for focal seizures

March 9, 2018 5:15 PM UTC

GW Pharmaceuticals plc (NASDAQ:GWPH) reported preliminary data from a Phase IIa trial in 162 adults with inadequately controlled focal seizures showing that twice-daily GWP42006 as an add-on therapy missed the primary endpoint of reducing focal seizure frequency from baseline to day 57 vs. placebo. Both arms reduced focal seizure frequency by about 40%. The company said the placebo response was "substantially greater" than the response reported in published studies of other treatments in similar patient populations. GWP42006 was generally well tolerated.

Secondary endpoints in the double-blind, European trial include safety, the number of treatment responders, change in seizure subtype frequency, composite seizure score, number of focal seizure-free days and rescue medication usage...

BCIQ Company Profiles

GW Pharmaceuticals plc

BCIQ Target Profiles

Cannabinoid receptors